证券代码:300692 证券简称:中赋科技 公告编号:2026-005 债券代码:123146 债券简称:中环转 2 安徽中赋源创科技集团股份有限公司 关于中环转 2 预计触发赎回条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 858,183,343.00 元。 经深交所同意，公司 864.00 万张可转换公司债券于 2022 年 5 月 26 日起在 深交所挂牌交易，债券简称"中环转 2"，债券代码"123146"。 （二）可转债债券利率 本次发行可转债票面利率为：第一年 0.30%、第二年 0.60%、第三年 1.00%、 第四年 1.60%、第五年 2.50%、第六年 3.00%。 特别提示： 截至本公告披露日，安徽中赋源创科技集团股份有限公司（以下简称"公司"） 股票价格自 2026 年 2 月 2 日至 2026 年 2 月 13 日已有十个交易日的收盘价格不 低于公司可转换公司债券（债券简称"中环转 2"，债券代码"123146"）当期 转股价格 6.23 元/股的 130%（含 130%，即 8.099 元/股）。如后续公司股 ...

| 证券代码:300692 | 证券简称:中赋科技 | 公告编号:2026-004 | | --- | --- | --- | | 债券代码:123146 | 债券简称:中环转 2 | | 安徽中赋源创科技集团股份有限公司 关于变更公司电子邮箱及新增公司网址的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 安徽中赋源创科技集团股份有限公司（以下简称"公司"）因公司名称及证 券简称变更，现对公司电子邮箱做相应变更并增设了公司网址。具体变更情况公 告如下： 一、变更公司电子邮箱 | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 公司电子邮箱 | zhhb@ahzhhb.cn | zfkj@orivietechnology.com | | 二、新增公司网址 | | --- | | 新增事项 | 新增前 | 新增后 | | --- | --- | --- | | 公司网址 | | http://www.ahzhhb.cn/ | | | http://www.ahzhhb.cn/ | http://orivietechnolo ...

Core Viewpoint - Liu Yang, a seasoned entrepreneur in the biopharmaceutical sector, has acquired a controlling stake in Zhongfu Technology (300692) for 598 million yuan, marking a strategic shift from environmental protection to a dual focus on "environmental protection + biopharmaceuticals" [1][2]. Group 1: Strategic Intent - The acquisition is described as a strategic exploration rather than mere capital arbitrage, aiming to build a biopharmaceutical ecosystem while integrating environmental protection [2][3]. - Liu Yang emphasizes that both sectors share a core logic of responsibility for life and health, aligning with national goals for carbon neutrality and the need for traditional environmental firms to seek new growth avenues [2]. Group 2: Governance and Transition - The previous controlling shareholder, Zhang Bozhong, relinquished some voting rights to ensure a smooth transition of control, highlighting a shared vision for the company's future beyond traditional environmental services [3]. - Liu Yang and Zhang Bozhong have reached a consensus on strategic direction, governance structure, and value creation, focusing on a dual-driven approach to overcome development bottlenecks [3]. Group 3: Business Development Plans - Liu Yang plans to upgrade existing environmental operations rather than replace them, aiming for improved management, asset structure, and operational efficiency to ensure stable cash flow and shareholder returns [4]. - The establishment of a wholly-owned subsidiary, Dingfu Pharmaceutical, will serve as the platform for implementing biopharmaceutical strategies, focusing on innovative projects with global commercialization potential [4][5]. Group 4: Capital Operations - The company is preparing for a targeted capital increase directed at Liu Yang, which will reinforce control and provide funding for new industry ventures [5]. - The recent rebranding from "Zhonghuan Environmental" to "Zhongfu Technology" reflects a commitment to biopharmaceuticals and strategic transformation [5]. Group 5: Long-term Vision - Liu Yang acknowledges the challenges of traditional enterprises entering new industries, stressing the importance of creating a genuine value ecosystem and avoiding superficial business overlaps [6]. - The company aims to enhance the quality of its environmental business while accelerating the industrialization of its biopharmaceutical segment, establishing a comprehensive business system for sustainable growth [7]. - Liu Yang envisions Zhongfu Technology evolving into a comprehensive technology platform that bridges green economy and life sciences, contributing to high-quality industrial development and maximizing shareholder value [8].

Core Viewpoint - Liu Yang, a seasoned entrepreneur in the biopharmaceutical sector, has acquired a controlling stake in Zhongfu Technology for 598 million yuan, marking a strategic shift from environmental protection to a dual focus on "environmental protection + biopharmaceuticals" [1][2] Group 1: Strategic Intent - The acquisition is described as a strategic exploration rather than mere capital arbitrage, aiming to build a biopharmaceutical ecosystem while integrating environmental protection [2][3] - Liu Yang emphasizes the shared core logic of "responsibility for life and health" between environmental protection and biopharmaceuticals, suggesting that both sectors can benefit from collaboration [2] Group 2: Governance and Control - The previous controlling shareholder, Zhang Bozhong, relinquished some voting rights to ensure a smooth transition of control, highlighting a mutual understanding of strategic direction and governance [3] - Liu Yang and Zhang Bozhong have reached a consensus on the future direction of Zhongfu Technology, focusing on a dual-driven approach to overcome development bottlenecks [3] Group 3: Business Development Strategy - Liu Yang plans to upgrade existing environmental protection operations rather than replace them, aiming for improved management and operational efficiency to ensure stable cash flow [4] - The company has established a wholly-owned subsidiary, Dingfu Pharmaceutical, to implement its biopharmaceutical strategy, focusing on high-potential projects with global commercialization capabilities [4] Group 4: Capital Operations - The company is preparing a targeted private placement to Liu Yang, which will strengthen control and provide funding for new industry initiatives [5] - The recent name change from "Zhonghuan Environmental Protection" to "Zhongfu Technology" reflects the commitment to biopharmaceuticals and strategic transformation [5] Group 5: Long-term Vision - Liu Yang outlines a clear vision for the next 3-5 years, focusing on enhancing the quality of environmental operations and accelerating the industrialization of the biopharmaceutical sector [7] - The goal is to transform Zhongfu Technology into a comprehensive technology platform that spans green economy and life sciences, contributing to high-quality industrial development and maximizing shareholder value [7]

Core Viewpoint - Zhongfu Technology (300692) announced a total guarantee amount of 356,330.05 million yuan, with a total balance of guarantees provided amounting to 292,830.05 million yuan, which represents 129.42% of the company's latest audited net assets for the fiscal year 2024 [1] Group 1 - The total guarantee amount includes a previous year guarantee balance of 221,830.05 million yuan and a current year guarantee balance of 71,000.00 million yuan [1] - All guarantees are related to wholly-owned and controlling subsidiaries, with no guarantees provided to entities outside the consolidated financial statements [1] - The company has no overdue external guarantees, no guarantees involved in litigation, and no losses incurred due to guarantees [1]

| 证券代码:300692 | 证券简称:中赋科技 | | 公告编号:2026-003 | | --- | --- | --- | --- | | 债券代码:123146 | 债券简称:中环转 | 2 | | 安徽中赋源创科技集团股份有限公司 关于子公司融资并由公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别风险提示： 截至本公告披露日，安徽中赋源创科技集团股份有限公司（以下简称"公 司"或"中赋科技"）及子公司的担保额度总金额合计 356,330.05 万元，提供担 保总余额合计 292,830.05 万元（其中，以前年度担保余额为 221,830.05 万元， 本年度担保余额为 71,000.00 万元），占公司最近一期（2024 年度）经审计净资 产的比例为 129.42%，均为对全资子公司、控股子公司发生的担保事项。除此 之外公司没有发生对合并报表外单位提供担保情况，公司无逾期的对外担保事 项，无涉及诉讼的担保金额以及因担保而产生损失的情况。请投资者充分关注 相关担保风险。 一、担保情况概述 公司第四届董事会第六次会议、第 ...

Core Viewpoint - Zhongfu Technology (300692) reported a closing price of 9.01 yuan as of January 30, 2026, reflecting a 0.33% increase with a turnover rate of 2.3% and a trading volume of 94,600 shares, amounting to a transaction value of 84.34 million yuan [1] Group 1 - The company is considering the early redemption of its convertible bonds ("Zhonghuan Convertible Bond 2") based on market conditions, actual company circumstances, and investor interests [2] - The company's recent capital increase has been approved by the board and shareholders, pending approval from the Shenzhen Stock Exchange and registration by the China Securities Regulatory Commission [2] - On January 30, the net outflow of funds from major investors was 2.0271 million yuan, while retail investors saw a net inflow of 4.5903 million yuan [2]

Summary of Key Points Core Viewpoint - On January 28, Zhongfu Technology executed a block trade of 532,600 shares at a transaction value of 4.4206 million yuan, representing 5.12% of the total trading volume for the day, with a transaction price of 8.30 yuan, which is a discount of 9.39% compared to the market closing price of 9.16 yuan [1]. Group 1 - The block trade involved 532,600 shares of Zhongfu Technology [2]. - The total transaction amount for the block trade was 4.4206 million yuan [1]. - The transaction price of 8.30 yuan was significantly lower than the market closing price of 9.16 yuan, indicating a discount of 9.39% [1].

Group 1 - The core viewpoint of the news is that Zhongfu Technology has shown a positive stock performance with a year-to-date increase of 10.48% and a recent rise of 2.09% in a single trading day, indicating strong market interest and potential growth [1] - As of January 14, Zhongfu Technology's stock price reached 9.28 yuan per share, with a market capitalization of 4.272 billion yuan and a trading volume of 55.269 million yuan [1] - The company primarily engages in wastewater treatment and environmental engineering, with its main revenue sources being investment operation services (81.34%) and engineering contracting services (18.58%) [1] Group 2 - As of September 30, Zhongfu Technology reported a total of 17,900 shareholders, a decrease of 2.14% from the previous period, while the average circulating shares per person increased by 2.81% to 21,097 shares [2] - For the period from January to September 2025, Zhongfu Technology achieved an operating income of 721 million yuan, representing a year-on-year growth of 2.99%, and a net profit attributable to shareholders of 84.601 million yuan, up 13.84% year-on-year [2] - The company has distributed a total of 111 million yuan in dividends since its A-share listing, with 50.114 million yuan distributed over the past three years [3]

Group 1 - The company aims to enhance its sustainable profitability and optimize asset quality while considering investments in high-quality projects in the biopharmaceutical sector to cultivate new profit growth points [2] - The specific business situation will be based on the company's disclosed periodic reports and temporary announcements [2]